Tandem Diabetes Care received FDA 510(k) clearance for Tandem Mobi, the world's first and only tubeless automated insulin delivery system with up to 7 days of wear. The clearance allows the pump to offer both tubed and tubeless infusion options, with a full commercial launch planned for the first half of 2027.
Tandem Diabetes Care reported sales of $283.7 million for the third quarter of 2026, a 14% increase year-over-year, while significantly narrowing its quarterly net loss to $7.1 million from $21.2 million in 2025. The company strengthened its balance sheet by issuing convertible senior notes due 2032, contributing to a total asset base of $1.16 billion as of September 30, 2026.
Tandem Diabetes Care reported Q3 2026 worldwide sales of $283.7 million, a 14% increase year-over-year, driven by strong international growth and expanded pump shipments. The company significantly narrowed its net loss to $7.1 million and reaffirmed its full-year 2026 sales guidance of $1.065 billion to $1.085 billion.
Term
Q3 2026
“Tandem’s third-quarter performance demonstrates that our strategy is delivering results. We are expanding access to Tandem’s life-changing technology, strengthening our business model, advancing our pipeline and driving greater operating efficiency, creating a stronger foundation for sustainable, profitable growth.”
John Sheridan, president and chief executive officer
Tandem Diabetes Care Insider Christopher J. Twomey Sells $32.6K of Stock
Christopher J. Twomey sold 1,700 shares of Tandem Diabetes Care Inc at $19.15 a share, worth $32.6K in total on Oct 27, 2026. Shares held after the trade: 24,434 (-6.5%).